---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057722"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:43:45.741234+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance Q1 net loss $107.4M, cash $632.7M; BLA submitted for lifileucel

## Summary
- Q1 net loss $107.4M ($0.50 per share) vs loss of $91.6M ($0.58) in Q1 2022.
- Cash $632.7M as of Mar 31, 2023, incl $260.1M from ATM facility; expected to fund into H2 2024.
- Completed rolling BLA submission for lifileucel in post-anti-PD-1 advanced melanoma in March 2023.
- Plans to acquire Proleukin; closing expected Q2 2023.
- Commercial launch preparations for lifileucel on track for 2023; iCTC capacity for 2,000+ patients.

## SEC filing metadata
- accession: 0001104659-23-057722
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/0001104659-23-057722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/tm2315161d1_8kseq1.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057722
- JSON: https://secwatch.observer/filing/0001104659-23-057722.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057722.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and an update on recent developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/0001104659-23-057722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.